|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HBA1 |
Gene summary for HBA1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HBA1 | Gene ID | 3039 |
| Gene name | hemoglobin subunit alpha 1 | |
| Gene Alias | ECYT7 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | D1MGQ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3039 | HBA1 | AEH-subject1 | Human | Endometrium | AEH | 8.15e-11 | -6.37e-01 | -0.3059 |
| 3039 | HBA1 | AEH-subject2 | Human | Endometrium | AEH | 3.58e-07 | -6.37e-01 | -0.2525 |
| 3039 | HBA1 | AEH-subject3 | Human | Endometrium | AEH | 3.72e-11 | -6.41e-01 | -0.2576 |
| 3039 | HBA1 | AEH-subject4 | Human | Endometrium | AEH | 2.33e-06 | -6.41e-01 | -0.2657 |
| 3039 | HBA1 | AEH-subject5 | Human | Endometrium | AEH | 9.05e-08 | -6.33e-01 | -0.2953 |
| 3039 | HBA1 | EEC-subject1 | Human | Endometrium | EEC | 4.58e-10 | -6.36e-01 | -0.2682 |
| 3039 | HBA1 | EEC-subject2 | Human | Endometrium | EEC | 1.26e-09 | -6.40e-01 | -0.2607 |
| 3039 | HBA1 | EEC-subject3 | Human | Endometrium | EEC | 4.42e-05 | -5.65e-01 | -0.2525 |
| 3039 | HBA1 | EEC-subject4 | Human | Endometrium | EEC | 2.73e-08 | -6.30e-01 | -0.2571 |
| 3039 | HBA1 | EEC-subject5 | Human | Endometrium | EEC | 3.72e-11 | -6.41e-01 | -0.249 |
| 3039 | HBA1 | GSM5276934 | Human | Endometrium | EEC | 1.78e-10 | -6.41e-01 | -0.0913 |
| 3039 | HBA1 | GSM5276935 | Human | Endometrium | EEC | 4.54e-08 | -6.26e-01 | -0.123 |
| 3039 | HBA1 | GSM5276937 | Human | Endometrium | EEC | 2.84e-06 | -6.34e-01 | -0.0897 |
| 3039 | HBA1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 7.38e-07 | -6.41e-01 | -0.1869 |
| 3039 | HBA1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 7.63e-06 | -6.41e-01 | -0.1875 |
| 3039 | HBA1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.48e-07 | -6.41e-01 | -0.1883 |
| 3039 | HBA1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 8.15e-11 | -6.39e-01 | -0.1934 |
| 3039 | HBA1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.81e-08 | -6.28e-01 | -0.1917 |
| 3039 | HBA1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 5.36e-10 | -6.41e-01 | -0.1916 |
| 3039 | HBA1 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.78e-10 | -6.41e-01 | -0.1269 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000697916 | Endometrium | AEH | response to oxidative stress | 93/2100 | 446/18723 | 1.94e-09 | 1.64e-07 | 93 |
| GO:000030216 | Endometrium | AEH | response to reactive oxygen species | 54/2100 | 222/18723 | 2.54e-08 | 1.49e-06 | 54 |
| GO:004254215 | Endometrium | AEH | response to hydrogen peroxide | 38/2100 | 146/18723 | 4.70e-07 | 1.92e-05 | 38 |
| GO:009723710 | Endometrium | AEH | cellular response to toxic substance | 34/2100 | 124/18723 | 5.02e-07 | 1.97e-05 | 34 |
| GO:199074810 | Endometrium | AEH | cellular detoxification | 30/2100 | 116/18723 | 8.40e-06 | 1.98e-04 | 30 |
| GO:000963610 | Endometrium | AEH | response to toxic substance | 52/2100 | 262/18723 | 2.89e-05 | 5.40e-04 | 52 |
| GO:009886910 | Endometrium | AEH | cellular oxidant detoxification | 26/2100 | 101/18723 | 3.57e-05 | 6.26e-04 | 26 |
| GO:009875410 | Endometrium | AEH | detoxification | 31/2100 | 152/18723 | 6.85e-04 | 6.62e-03 | 31 |
| GO:00427439 | Endometrium | AEH | hydrogen peroxide metabolic process | 14/2100 | 58/18723 | 4.12e-03 | 2.73e-02 | 14 |
| GO:00427445 | Endometrium | AEH | hydrogen peroxide catabolic process | 9/2100 | 32/18723 | 7.02e-03 | 4.07e-02 | 9 |
| GO:000697917 | Endometrium | EEC | response to oxidative stress | 99/2168 | 446/18723 | 9.02e-11 | 1.13e-08 | 99 |
| GO:000030217 | Endometrium | EEC | response to reactive oxygen species | 57/2168 | 222/18723 | 4.04e-09 | 2.82e-07 | 57 |
| GO:004254216 | Endometrium | EEC | response to hydrogen peroxide | 41/2168 | 146/18723 | 4.12e-08 | 2.29e-06 | 41 |
| GO:009723715 | Endometrium | EEC | cellular response to toxic substance | 35/2168 | 124/18723 | 3.44e-07 | 1.37e-05 | 35 |
| GO:199074815 | Endometrium | EEC | cellular detoxification | 31/2168 | 116/18723 | 5.54e-06 | 1.36e-04 | 31 |
| GO:000963615 | Endometrium | EEC | response to toxic substance | 54/2168 | 262/18723 | 1.65e-05 | 3.18e-04 | 54 |
| GO:009886915 | Endometrium | EEC | cellular oxidant detoxification | 27/2168 | 101/18723 | 2.17e-05 | 3.89e-04 | 27 |
| GO:009875415 | Endometrium | EEC | detoxification | 32/2168 | 152/18723 | 5.52e-04 | 5.52e-03 | 32 |
| GO:004274313 | Endometrium | EEC | hydrogen peroxide metabolic process | 14/2168 | 58/18723 | 5.49e-03 | 3.33e-02 | 14 |
| GO:004274411 | Endometrium | EEC | hydrogen peroxide catabolic process | 9/2168 | 32/18723 | 8.63e-03 | 4.70e-02 | 9 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HBA1 | SNV | Missense_Mutation | c.328N>A | p.Leu110Met | p.L110M | P69905 | protein_coding | tolerated(0.12) | benign(0.293) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HBA1 | SNV | Missense_Mutation | novel | c.420A>C | p.Lys140Asn | p.K140N | P69905 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HBA1 | SNV | Missense_Mutation | novel | c.103N>A | p.Leu35Met | p.L35M | P69905 | protein_coding | tolerated(0.09) | benign(0.026) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| HBA1 | SNV | Missense_Mutation | c.26N>A | p.Thr9Asn | p.T9N | P69905 | protein_coding | tolerated(0.17) | benign(0) | TCGA-BS-A0TG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| HBA1 | SNV | Missense_Mutation | novel | c.17N>T | p.Ala6Val | p.A6V | P69905 | protein_coding | tolerated(0.17) | benign(0.01) | TCGA-EO-A22S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |